Here are the 10-K annual reports from Neuraxis, Inc. (NRXS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow NRXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NRXS filings page.
Neuraxis, Inc. develops drug-free neuromodulation devices for chronic gastrointestinal and pain conditions, focusing initially on pediatric patients with disorders of gut-brain interaction. Its lead product, IB-Stim, is an FDA Class II PENFS device for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia in patients 8 years and older.
The company has also launched RED (Rectal Expulsion Device) for office-based assessment of pelvic floor dysfunction and rectal hypersensitivity in adults, and has additional PENFS indications in randomized trials, including post-concussion syndrome, cyclic vomiting syndrome, post-operative opioid-sparing pain control and fibromyalgia.
IB-Stim is priced at $1,195 per device, or $4,780 per standard four-device treatment course. Key access milestones include a Category I CPT code 64567 effective January 1, 2026, inclusion of PENFS as the only FDA-cleared treatment in NASPGHAN pediatric functional abdominal pain guidelines, and a Federal Supply Schedule contract for IB-Stim. As of March 12, 2026, Neuraxis had 11,187,639 common shares outstanding, and non-affiliate equity was valued at approximately $20.4 million at its most recent second-quarter end.